Genmab Unlocks 2025: R&D, ASH Data, Pipeline Strategy Revealed
The Biotech Beat: What Genmab’s Latest R&D Update Means for Your Portfolio Hey everyone, Sarah Miller here! Over my 10+ years diving deep into market analysis and financial research, I’ve seen my share of company updates – some are just noise, and some, well, they really get my gears turning. Recently, Genmab A/S (GMAB) dropped some insights into their 2025 R&D progress, shared an ASH (American Society of Hematology) data review, and talked about strategic pipeline additions in a recent slideshow. ...